Standout Papers

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose 2008 2026 2014 2020 1.0k
  1. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose (2008)
    Christine H. Chung, Beloo Mirakhur et al. New England Journal of Medicine
  2. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (2016)
    Padmanee Sharma, Margaret K. Callahan et al. The Lancet Oncology
  3. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer (2015)
    Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology

Immediate Impact

9 by Nobel laureates 28 from Science/Nature 58 standout
Sub-graph 1 of 24

Citing Papers

Targeting KRAS in cancer
2024 Standout
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
2021 Standout

Works of Emily Chan being referenced

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
2015 Standout

Author Peers

Author Last Decade Papers Cites
Emily Chan 2068 1348 1669 90 4.7k
Francis Y. Lee 1707 649 2346 102 7.2k
Bronislaw Pytowski 3527 1080 3433 61 6.4k
Sufi M. Thomas 2151 420 2616 101 5.1k
H. Baisch 1548 688 1931 57 5.5k
Maria Flavia Di Renzo 1906 1344 4032 105 7.3k
Jerry Ware 1015 1057 1942 146 8.2k
Kenneth E. Lipson 1236 516 3261 119 6.1k
G. David Roodman 5156 758 3054 129 7.5k
Pipsa Saharinen 2509 539 3454 68 6.3k
G. Kenneth Haines 2138 679 2029 91 6.5k

All Works

Loading papers...

Rankless by CCL
2026